Successful dabigatran reversal after subdural hemorrhage using idarucizumab in a mobile stroke unit

A case report

Sibi Thirunavukkarasu, MD, FRCP, Hayrapet Kalashyan, MD, FRCP, Glen Jickling, FRCP, Thomas Joseph Jeerakathil, FRCP, Harsha Kamble Jayaprakash, MD, Brian H. Buck, FRCP, Ashfaq Shuaib, FRCP, Ken Butcher, FRCP

Abstract

Rationale: Idarucizumab is a specific reversal agent for patients with bleeding related to the anticoagulant dabigatran. There are no prior descriptions of Idarucizumab administration in the prehospital setting for intracranial hemorrhage.

Patient concerns: An 82-year-old woman treated with dabigatran for atrial fibrillation developed acute focal weakness. This led to activation of emergency medical services and assessment in the mobile stroke unit (MSU).

Diagnosis: Computed tomography of the brain performed in the MSU revealed an acute subdural hematoma.

Interventions: The patient was treated with Idarucizumab in the MSU.

Outcomes: The subdural hematoma was treated with a burr hole evacuation and the patient was discharged to a rehabilitation facility without residual focal neurological deficits.

Lessons: Idarucizumab can be used safely and effectively to treat dabigatran-associated intracranial hemorrhage in the prehospital setting.

Abbreviations: ACHIEVE = AmbulanCe Housed Ischemic stroke trEatment with intraVE-nous thrombolysis, CT = computed tomography, MSU = mobile stroke unit, PTT = partial thromboplastin time, TT = thrombin time.

Keywords: antibodies, anticoagulant agents, dabigatran, hematoma subdural, humanized, Idarucizumab, monoclonal

1. Introduction

Idarucizumab is a specific reversal agent for patients with bleeding related to the anticoagulant dabigatran.[11] Current guidelines recommend reversal of antiagulation in patients acutely bleeding at critical sites including the brain, spinal cord, and pericardium.[21] There is evidence that anticoagulant-associated intracerebral hematomas expand more frequently, with subsequent neurological deterioration and poor functional outcome, than in patients not taking anticoagulants.[3,4,5] Rapid reversal of the coagulopathy is therefore recommended.[6] Although there are sparse data related to subdural hemorrhage expansion in anticoagulated patients, the principle of rapid reversal is also applicable.[7]

Idarucizumab has been used to treat dabigatran-associated intracranial hemorrhage acutely in hospital.[8] There are currently no reports of reversal of dabigatran related bleeding in the pre-hospital setting. We are currently evaluating the utility of a mobile stroke unit (MSU) in a rural setting.[9] Following approval of Idarucizumab, this drug was placed on the MSU. We describe Idarucizumab administration in the MSU after diagnosis of a dabigatran-related subdural hemorrhage (SDH).

2. Case summary

An 82-year-old, right-handed woman, was assessed as part of the AmbulanCe Housed Ischemic Stroke trEatment with intraVE-nous Thrombolysis (ACHIEVE) study.[10,11] The study was approved by University of Alberta Health Research Ethics Board; ID - Pro00037601. The patient provided informed consent for publication of this report.

The patient was taking dabigatran 110mg, twice daily for atrial fibrillation (AF), on the day of assessment, she developed
sudden onset left sided facial droop and dysarthria. As part of the ACHIEVE study she was assessed in the MSU, which is equipped with a computed tomography (CT) scanner (Ceretom).

The past medical history was significant for coronary artery bypass grafting, and a fall 2 weeks prior to symptom onset. The patient confirmed taking dabigatran on the day of symptom onset. Examination in the MSU 1 hour after symptom onset revealed upper motor neuron pattern left facial weakness and moderate dysarthria. Mobile CT scan demonstrated a right subdural hematoma (Fig. 1). Point of care testing for dabigatran levels was not available on the MSU.

The patient was treated with Idarucizumab 5g intravenously in the MSU. Thrombin time (TT) and partial thromboplastin time (aPTT) after arrival at hospital were 16.6 seconds (Normal range 14.3–19.7) and 25 seconds (Normal 27–38) respectively. The patient was admitted to the neurosurgery service and managed conservatively. Repeat CT scan 72 hours later demonstrated a stable subdural hematoma (Fig. 1). Point of care testing for dabigatran levels was not available on the MSU.

The patient was treated with Idarucizumab 5g intravenously in the MSU. Thrombin time (TT) and partial thromboplastin time (aPTT) after arrival at hospital were 16.6 seconds (Normal range 14.3–19.7) and 25 seconds (Normal 27–38) respectively. The patient was admitted to the neurosurgery service and managed conservatively. Repeat CT scan 72 hours later demonstrated a stable subdural hematoma (Fig. 1). A burr hole evacuation procedure was performed on day 4. Following burr hole trephination, the patient was discharged to a rehabilitation facility. At the time of discharge, the patient did not have any focal neurological deficits.

3. Discussion

Idarucizumab is a specific reversal agent for the anticoagulant dabigatran that has been shown to normalize clotting indices including TT, in patients presenting with bleeding or requiring urgent surgery. The treatment priority in anticoagulant-associated intracranial bleeding is reversal of the coagulopathy and attenuation of hematoma expansion. Hematoma expansion tends to occur early and therefore rapid reversal is recommended.

Although a pre-treatment TT/aPTT were not available on the MSU, the patient did confirm taking dabigatran the day of symptom onset, suggesting she was therapeutically anticoagulated at the time of assessment. The normal post-treatment TT and stability of the subdural hematoma on CT scans suggests successful treatment in our patient.

Although the primary aim of pre-hospital stroke programs is thrombolysis for ischemic stroke, the mobile CT also facilitates the early diagnosis of intracranial hemorrhage and rapid reversal in anticoagulant associated cases. For this reason, the MSU carries prothrombin concentrate complex for vitamin K antagonist related intracranial bleeding. Idarucizumab was placed on the MSU soon after approval for use in Canada. Currently, there is no specific reversal agent for patients taking factor Xa antagonists including rivaroxaban, apixaban and edoxaban. Patients with Xa antagonist related bleeding are currently treated empirically with prothrombin complex concentrate (PCC) as per treatment guidelines.

Idarucizumab can also be used to reverse the effects of dabigatran in patients presenting with ischemic stroke symptoms in order to facilitate thrombolysis. In fact, the only previous report of Idarucizumab use for stroke in the pre-hospital setting was for this purpose, reflecting the fact that ischemic stroke remains more common than intracranial bleeding in patients with atrial fibrillation who are anticoagulated.
Summary: Idarucizumab can be used safely and effectively to treat dabigatran-associated intracranial hemorrhage in the prehospital setting. We suggest mobile units carry reversal agents, including Idarucizumab, prothrombin complex concentrate and where approved/available, andexanet alpha for management of Xa antagonist associated bleeding.[18,19]

Author contributions

Investigation: Hayrapet Kalashyan.
Methodology: Hayrapet Kalashyan, Glen Jickling, Ken Butcher.
Resources: Sibi Thirunavukkarasu.
Supervision: Ashfaq Shuaib, Ken Butcher.
Validation: Sibi Thirunavukkarasu, Ken Butcher.
Writing – original draft: Sibi Thirunavukkarasu, Hayrapet Kalashyan, Glen Jickling, Thomas Joseph Jeerakathil, Harsha Kamble Jayaprakash, Brian Hilton Buck, Ashfaq Shuaib, Ken Butcher.
Writing – review & editing: Sibi Thirunavukkarasu, Hayrapet Kalashyan, Glen Jickling, Thomas Joseph Jeerakathil, Brian Hilton Buck, Ken Butcher.

References

[1] Eikelboom John W, Quinlan Daniel J, van Ryn Joanne, et al. Idarucizumab. Circulation 2015;132:2412–22.
[2] Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol 2017;70:3042–67.
[3] Seiffge DJ, Goeklidin MB, Tatlisumak T, et al. Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use. J Neurol 2019;266:3126–35.
[4] Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008;39:2993–6.
[5] Wilson D, Seifffe DJ, Traenka C, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology 2017;88:1693–700.
[6] Levy JH, Agno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost JTH 2016;14:623–7.
[7] Kermer P, Eschenfelder CC, Diener H-C, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection. Int J Stroke Off J Int Stroke Soc 2017;12:383–91.
[8] Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med 2017;377:431–41.
[9] Shuaib A, Jeerakathil T. The mobile stroke unit and management of acute stroke in rural settings. CMAJ Can Med Assoc J 2018;190:E855–8.
[10] Shuaib A, Amlani S, Kalashyan H, et al. Mobile stroke unit triage of patients with a suspected stroke: a novel solution to reducing suspected stroke admissions in busy emergency departments. BMJ Innov 2018;4:34–9.
[11] Shuaib A, Jeerakathil T. Alberta Mobile Stroke Unit InvestigatorsThe mobile stroke unit and management of acute stroke in rural settings. CMAJ Can Med Assoc J J Assoc Medicale Can 2018;190:E855–8.
[12] Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511–20.
[13] Casaubon JK, Boulanger JM, Blaiscquier D, et al. Canadian stroke best practice recommendations: hyperacute stroke care guidelines, Update 2015. Int J Stroke Off J Int Stroke Soc 2015;10:924–40.
[14] Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015;46:2032–60.
[15] Diener HC, Bernstein R, Butcher K, et al. Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion. Int J Stroke Off J Int Stroke Soc 2017;12:9–12.
[16] Harsha KJ, Thirunavukkarasu S, Butcher K. Acute stroke thrombolysis following dabigatran reversal using idarucizumab. Neurol India 2019; 67:368–70.
[17] Zhao H, Coote S, Pesavento L, et al. Prehospital idarucizumab prior to intravenous thrombolysis in a mobile stroke unit. Int J Stroke Off J Int Stroke Soc 2019;14:265–9.
[18] Steiner T, Poli S, Gribe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH); a randomised trial. Lancet Neurol 2016;15:566–73.
[19] Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131–41.